Mirae Asset Global ETFs Holdings’s Crinetics Pharmaceuticals CRNX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.79M	Buy	47,762 +1,915	+4%	+$71.2K	﹤0.01%	1310
2026 Q1	$1.67M	Buy	45,847 +3,845	+9%	+$172K	﹤0.01%	1260
2025 Q4	$1.96M	Sell	42,002 -7	-0%	-$312	﹤0.01%	1157
2025 Q3	$1.75M	Sell	42,009 -11,986	-22%	-$383K	﹤0.01%	1204
2025 Q2	$1.56M	Sell	53,995 -5,316	-9%	-$164K	﹤0.01%	1223
2025 Q1	$1.99M	Buy	59,311 +6,148	+12%	+$230K	﹤0.01%	1144
2024 Q4	$2.72M	Buy	53,163 +6,719	+14%	+$376K	0.01%	971
2024 Q3	$2.37M	Buy	46,444 +8,054	+21%	+$415K	0.01%	1046
2024 Q2	$1.71M	Buy	+38,390	New	+$1.77M	﹤0.01%	1152

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CRNX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Crinetics Pharmaceuticals (CRNX) stake by 4.2% in Q2 2026, buying an estimated $71.2K and bringing the position to 47,762 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1310.

Mirae Asset Global ETFs Holdings first reported a position in CRNX in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.72M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Mirae Asset Global ETFs Holdings held 47,762 shares of Crinetics Pharmaceuticals worth $1.79M as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 1,915 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $71.2K.
Crinetics Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1310 holding.
Mirae Asset Global ETFs Holdings first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Mirae Asset Global ETFs Holdings's Crinetics Pharmaceuticals position peaked at $2.72M in Q4 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.